ArticleThe American journal of pathology2010
Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma.
Article in The American journal of pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 46 citations in OpenAlex.
- Computational-experimental strategy identifies Co-upregulated biomarkers linking coronary heart disease and type 2 diabetes pathogenesis.Frontiers in genetics · 2025Article
- The expression and role of SUZ12 in lung adenocarcinoma.Cancer medicine · 2024Article
- Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics.Drug discovery today · 2024Review
- PRC2 mediated KLF2 down regulation: a therapeutic and diagnostic axis during tumor progression.Cancer cell international · 2023Review
- IL-1β-Triggered Long Non-coding RNA CHRF Induces Non-Small Cell Lung Cancer by Modulating the microRNA-489/Myd88 Axis.Journal of Cancer · 2022Article
- Article
- Crosstalk between microglia and patient-derived glioblastoma cells inhibit invasion in a three-dimensional gelatin hydrogel model.Journal of neuroinflammation · 2020Article
- Deregulation of Polycomb Repressive Complex-2 in Mantle Cell Lymphoma Confers Growth Advantage by Epigenetic Suppression ofFrontiers in oncology · 2020Article
- miR‑767‑5p inhibits glioma proliferation and metastasis by targeting SUZ12.Oncology reports · 2019Article
- TRPS1 Suppresses Breast Cancer Epithelial-mesenchymal Transition Program as a Negative Regulator of SUZ12.Translational oncology · 2018Article
- Polycomb Repressor Complex 2 in Genomic Instability and Cancer.International journal of molecular sciences · 2017Review
- Association of the long non-coding RNA MALAT1 with the polycomb repressive complex pathway in T and NK cell lymphoma.Oncotarget · 2017Article
- Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications.Medicinal research reviews · 2015Review
- Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- SUZ12 promotes gastric cancer cell proliferation and metastasis by regulating KLF2 and E-cadherin.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- ARE/SUZ12 dual specifically-regulated adenoviral TK/GCV system for CML blast crisis cells.Journal of experimental & clinical cancer research : CR · 2015Article
- Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.Journal of cancer research and clinical oncology · 2015Article
- Review
- MiR-449a suppresses cell invasion by inhibiting MAP2K1 in non-small cell lung cancer.American journal of cancer research · 2015Article
- SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycomb proteins are known to be of great importance in human cancer pathogenesis. SUZ12 is a component of the Polycomb PRC2 complex that, along with EZH2, is involved in embryonic stem cell differentiation. EZH2 plays an essential role in many cancer types, but an equivalent involvement of SUZ12 has not been as thoroughly demonstrated. Here we show that SUZ12 is anomalously expressed in human primary tumors, especially in mantle cell lymphoma (MCL), pulmonary carcinomas and melanoma, and is associated with gene locus amplification in some cases. Using MCL as a model, functional and genomic studies demonstrate that SUZ12 loss compromises cell viability, increases apoptosis, and targets genes involved in central oncogenic pathways associated with MCL pathogenesis. Our results support the hypothesis that the abnormal expression of SUZ12 accounts for some of the unexplained features of MCL, such as abnormal DNA repair and increased resistance to apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.